The transcriptional upregulation of oncogenes is a driving force behind the progression of
many tumours. However, until a decade ago, the concept of 'switching off'these oncogenic …

Liquid–liquid phase separation (LLPS) is a novel principle for explaining the precise spatial
and temporal regulation in living cells. LLPS compartmentalizes proteins and nucleic acids …

Immunotherapies that target programmed cell death protein 1 (PD-1) and its ligand PD-L1
as well as cytotoxic T-lymphocyte-associated protein 4 (CTLA4) have shown impressive …

Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

Despite the high long-term survival in localized prostate cancer, metastatic prostate cancer
remains largely incurable even after intensive multimodal therapy. The lethality of advanced …

Treatments that target immune checkpoints, such as the one mediated by programmed cell
death protein 1 (PD-1) and its ligand PD-L1, have been approved for treating human …

Less than a decade ago, it was shown that bromodomains, acetyl lysine 'reader'modules
found in proteins with varied functions, were highly tractable small-molecule targets. This is …

By hijacking endogenous E3 ligase to degrade protein targets via the ubiquitin-proteasome
system, PROTACs (PRoteolysis TArgeting Chimeras) provide a new strategy to inhibit …

Mutations in the tumor suppressor SPOP (speckle-type POZ protein) cause prostate, breast,
and other solid tumors. SPOP is a substrate adaptor of the cullin3-RING ubiquitin ligase and …

Proteolysis targeting chimera (PROTAC) is an emerging protein degradation strategy, which
shows excellent advantages in targeting those so-called “undruggable” proteins. However …